Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Targeted antibody ventures Mersana and CytomX attract venture dollars amid partnering promise

This article was originally published in Scrip

Executive Summary

Companies on opposite US coasts announced venture capital funding on 31 July to boost next-generation targeted discovery and development platforms. Cambridge, Massachusetts-based antibody-drug conjugate (ADC) specialist Mersana Therapeutics raised $27 million in a Series A-1 round and CytomX Therapeutics in San Francisco increased its Series B round to $41 million for its tissue-specific antibodies.


Related Content

VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts